1. Home
  2. VERV

VERV

Verve Therapeutics Inc.

Logo Verve Therapeutics Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Founded: 2018 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 635.5M IPO Year: 2021
Target Price: $35.33 AVG Volume (30 days): 1.3M
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.12 EPS Growth: N/A
52 Week Low/High: $7.36 - $21.42 Next Earning Date: 05-13-2024
Revenue: $11,758,000 Revenue Growth: 505.77%
Revenue Growth (this year): 25.4% Revenue Growth (next year): -32.64%

Share on Social Networks: